KRAS and pancreatic adenocarcinoma: Cohen et al. analysed 221 patients with resectable pancreatic adenocarcinoma, and the serum KRAS level in combination with other biomarkers, such as osteopontin, CA19-9, and circulating DNA, obtained a sensitivity of 64% and a specificity of 99.5% [157].